참고문헌
- Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119:1429-1437. https://doi.org/10.1172/JCI36183
- Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139:871-890. https://doi.org/10.1016/j.cell.2009.11.007
- van Zijl F, Zulehner G, Petz M, Schneller D, Kornauth C, Hau M, et al. Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol. 2009;5:1169-1179. https://doi.org/10.2217/fon.09.91
- Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15:178-196. https://doi.org/10.1038/nrm3758
- Kim SM, Han JH, Park SM. The role of epithelial-mesenchymal transition in the gastroenterology. Kor J Gastroenterol. 2010; 56:69-77. https://doi.org/10.4166/kjg.2010.56.2.69
- Chen PN, Hsieh YS, Chiou HL Chu SC. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact. 2005;156:141-150. https://doi.org/10.1016/j.cbi.2005.08.005
- Cufi S, Bonavia R, Vazquez-Martin A, Corominas-Faja B, Oliveras-Ferraros C, Cuyas E, et al. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food Chem Toxicol. 2013;60:360-368. https://doi.org/10.1016/j.fct.2013.07.063
- Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010;29:447-463. https://doi.org/10.1007/s10555-010-9237-0
- Deep G, Gangar SC, Agarwal C, Agarwal R. Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila). 2011;4:1222-1232. https://doi.org/10.1158/1940-6207.CAPR-10-0370
- Skottova N, Krecman V, Simanek V. Activities of silymarin and its flavonolignans upon low density lipoprotein oxidizability in vitro. Phytother Res. 1999;13:535-537. https://doi.org/10.1002/(SICI)1099-1573(199909)13:6<535::AID-PTR526>3.0.CO;2-W
-
Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T, et al. Silibinin inhibits
$\beta$ -catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Cell Signal. 2013;25:2625-2633. https://doi.org/10.1016/j.cellsig.2013.08.028 -
Hsieh MJ, Lin CW, Yang SF, Chen MK, Chiou HL. Glabridin inhibits migration and invasion by transcriptional inhibition of matrix metalloproteinase 9 through modulation of NF-
${\kappa}B$ and AP-1 activity in human liver cancer cells. Br J Pharmacol. 2014; 171:3037-3050. https://doi.org/10.1111/bph.12626 - Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39: 305-318. https://doi.org/10.1080/00313020701329914
- Hu L, Lau SH, Tzang CH, Wen JM, Wang W, Xie D, et al. Association of vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene. 2004;23:298-302. https://doi.org/10.1038/sj.onc.1206483
- Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007;67:2497-2507. https://doi.org/10.1158/0008-5472.CAN-06-3075
- National Cancer Information Center (KR). Cancer statistics. Cancer incidence in 2015 [Internet]. Goyang: National Cancer Information Center; 2015 [Cited 2018 June 04]. Available from: https://www.cancer.go.kr/lay1/S1T639C641/contents.do.
- National Cancer Information Center (KR). Cancer statistics. Liver cancer incidence by histology group in 2015 [Internet]. Goyang: National Cancer Information Center; 2015 [Cited 2018 June 04]. Available from: https://www.cancer.go.kr/lay1/program/S1T211C216/cancer/view.do?cancer_ seq=3317&menu_seq=3322.
- Tang ZY. Hepatocellular carcinoma--cause, treatment and metastasis. World J Gastroenterol. 2001;7:445-454. https://doi.org/10.3748/wjg.v7.i4.445
- Lee HS, Choi GH, Hwang HK, Kang CM, Choi JS, Lee WJ. The risk factors for extrahepatic recurrence after curative resection of hepatocellular carcinoma. Ann Hepatobiliary Pancreat Surg. 2010;14:227-234.
- Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229-235. https://doi.org/10.1097/01.sla.0000197706.21803.a1
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;16:704-715.
- Gilles C, Polette M, Zahm JM, Tournier JM, Volders L, Foidart JM, et al. 1999. Vimentin contributes to human mammary epithelial cell migration. J Cell Sci. 1999;112:4615-4625.
- Huang C, Jacobson K, Schaller, MD. A role for jnk-paxillin signaling in cell migration. Cell Cycle. 2004;3:4-6.
- Huang C, Jacobson K, Schaller MD. Map kinases and cell migration. J Cell Sci. 2004;117(Pt 20):4619-4628. https://doi.org/10.1242/jcs.01481
- Hsieh YS, Chu SC, Yang SF, Chen PN, Liu YC, Lu KH. Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis. 2007;28:977-987.
- Lee SO, Jeong YJ, Im HG, Kim CH, Chang YC, Lee IS. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun. 2007; 354:165-171. https://doi.org/10.1016/j.bbrc.2006.12.181